Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1856-1863

  Bevan, John S ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; MICROSPHERE; OCTREOTIDE; PENTETREOTIDE IN 111; POLYMER; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; SOMATOSTATIN;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; CELL STRUCTURE; DRUG EFFECT; EXAMINATION; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; PREDICTION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN SYNTHESIS; REVIEW; SYMPTOM; TUMOR VOLUME; HYPOPHYSIS TUMOR; PATHOLOGY;

ACROMEGALY; HUMANS; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 15944427116     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1093     Document Type: Review

References (77)

1. Brazeau P, Guillemin R 1974 Somatostatin: newcomer from the hypothalamus. N Engl J Med 290:963-964 (editorial)
2. Parker DC, Rossman LG, Siler TM, Rivier J, Yen SSC, Guillemin R 1974 Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J Clin Endocrinol Metab 38:496-499
3. Peracchi M, Reschini E, Cantalamessa L, Giustina G, Cavagnini F, Pinto M, Bulgheroni P 1974 Effect of somatostatin on blood glucose, plasma growth hormone, insulin, and free fatty acids in normal subjects and acromegalic patients. Metabolism 23:1009-1015
4. Yen SSC, Siler TM, DeVane GW 1974 Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. N Engl J Med 290:935-938
5. Giustina G, Peracchi M, Reschini E, Panerai AE, Pinto M 1975 Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients. Metabolism 24:807-815
6. Hansen AP, Lundbæk K 1976 Somatostatin: a review of its effects especially in human beings. Diabetes Metab 2:203-218
7. Faure N, Dussault JH, Nadeau A, Szots F, Guyda H, Labrie F 1977 Effect of somatostatin on thyrotropin, prolactin, growth hormone and insulin responses to thyrotropin releasing hormone and arginine in healthy, hypothyroid and acromegalic subjects. Can Med Assoc J 117:478-481
8. Hall R, Snow M, Scanlon M, Mora B, Gomez-Pan A 1978 Pituitary effects of somatostatin. Metabolism 27(Suppl 1):1257-1262
9. Culler M-D, Taylor J-E, Moreau J-P 2002 Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann Endocrinol 63:2S5-2S12
10. Lu H-T, Salamon H, Horuk R 2001 The biology and physiology of somatostatin receptors. Expert Opin Ther Targets 5:613-623
11. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C 2000 Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol 94:205-210
12. Benali N, Ferjoux G, Puente E, Buscail L, Susini C 2000 Somatostatin receptors. Digestion 62(Suppl 1):27-32
13. Hofland LJ, Lamberts SWJ 2001 Somatostatin receptor subtype expression in human tumors. Ann Oncol 12(Suppl 2):S31-S36
14. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik L'H 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792
15. Reubi JC, Kvols L, Krenning E, Lamberts SWJ 1990 Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39(Suppl 2):78-81
16. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JGM, Lamberts SWJ 1987 Somatostatin receptors in human endocrine tumors. Cancer Res 47:551-558
17. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
18. de Herder WW, Lamberts SWJ 2002 Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 14:53-57
19. Lamberts SWJ 1991 Somatostatin analogs: their role in the treatment of growth hormone hypersecretion and excessive body growth. Growth Regul 1:3-10
20. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
21. Battershill PE, Clissold SP 1989 Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 38:658-702
22. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
23. Anthony LB 1999 Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 31(Suppl 2):S216-S218
24. Lancranjan I, Bruns C, Grass P, Jaquet P, Jarvell J, Kendall-Taylor P, Lamberts SWJ, Marbach P, Ørskov H, Pagani G, Sheppard M, Simionescu L 1996 Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45(Suppl 1):67-71
25. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results by ROC analysis. J Clin Endocrinol Metab 88:3090-3098
26. Lightman S 2002 Somatuline autogel: an extended release lanreotide formulation. Hosp Med 63:162-165
27. García de la Torre N, Wass JAH, Turner HE 2002 Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425-441
28. Lamberts SWJ, Reubi J-C, Krenning EP 1994 The role of somatostatin analogs in the control of tumor growth. Semin Oncol 21(Suppl 13):61-64
29. Buscail L, Estève J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A-M, Bell GI, Schally AV, Vaysse N, Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584
30. Cordelier P, Estève J-P, Bousquet C, Delesque N, O'Carroll A-M, Schally AV, Vaysse N, Susini C, Buscail L 1997 Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 94:9343-9348
31. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi J-C, Lamberts SWJ 1992 Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 131:571-577
32. Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y 2002 Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65:200-206
33. Lee J-U, Hosotani R, Wada M, Doi R, Koshiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Hirohashi M, Uehara T, Arano Y, Fujii N, Imamura M 2002 Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells. Eur J Cancer 38:1526-1534
34. Santini V, Lamberts SWJ, Krenning EP, Backx B, Löwenberg B 1995 Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. Leuk Res 19:707-712
35. Sharma K, Patel YC, Srikant CB 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696
36. 1 cell cycle arrest. Mol Endocrinol 13:82-90
37. Weckbecker G, Raulf F, Bodmer D, Bruns C 1997 Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Yale J Biol Med 70:549-554
38. Lichtenauer-Kaligis EGR, van Hagen PM, Lamberts SWJ, Hofland LJ 2000 Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 143(Suppl 1):S21-S25
39. van Hagen PM, Hofland LJ, ten Bokum AMC, Lichtenauer-Kaligis EGR, Kwekkeboom DJ, Ferone D, Lamberts SWJ 1999 Neuropeptides and their receptors in the immune system. Ann Med 31(Suppl 2):15-22
40. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, Lamberts SWJ 1994 Somatostatin and the immune and haematopoietic system; a review. Eur J Clin Invest 24:91-99
41. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M 2001 Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194-5200
42. Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, Li J, Laws Jr ER 1997 Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72:893-900
43. Ezzat S, Horvath E, Harris AG, Kovacs K 1994 Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79:113-118
44. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
45. Bevan JS, Atkin SL, Atkinson AB, Bouloux P-M, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
46. Abe T, Lüdecke DK 2001 Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137-145
47. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G, and the Italian Multicenter Octreotide Study Group 1995 Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Eur J Endocrinol 133:430-439
48. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 66:16-23
49. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ 1988 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040-1048
50. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, Del Pozo E 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 64:447-453
51. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
52. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S 1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117:711-718
53. Horikawa R, Takano K, Hizuka N, Asakawa K, Sukegawa I, Hirose N, Horiba N, Kasono K, Masuda A, Ohba V, Nakagami Y, Tsushima T, Shizume K 1988 Treatment of acromegaly with long acting somatostatin analogue SMS 201-995. Endocrinol Jpn 35:741-751
54. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J 1999 Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399-405
55. Lamberts SWJ, del Pozo E 1988 Acute and long-term effects of SMS 201-995 in acromegaly. Scand J Gastroenterol 21(Suppl 119):141-148
56. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barceló B 1994 Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81:10-14
57. Lundin P, Engström BE, Karlsson FA, Burman P 1997 Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol 18:765-772
58. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
59. Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pendoncelli A, Tonnarelli GP 1990 Medical management of acromegaly: effects of SMS 201-995 in 30 patients. Endocrinol Exp 24:175-185
60. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe H-J 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79:1416-1423
61. Sassolas G, Harris AG, James-Deidier A 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 71:391-397
62. Shi YF, Harris AG, Zhu XF, Deng JY 1990 Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients. Clin Endocrinol (Oxf) 32:695-705
63. Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER 1987 Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh) 114:249-256
64. Stevenaert A, Harris AG, Kovacs K, Beckers A 1992 Presurgical octreotide treatment in acromegaly. Metabolism 41(Suppl 2):51-58
65. Tolis G, Yotis A, del Pozo E, Pitoulis S 1986 Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly. J Neurosurg 65:37-40
66. Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 151:1573-1578
67. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71
68. Attanasio R, Barausse M, Cozzi R 2001 GH/IGF-1 normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 24:209-216
69. Baldelli R, Colao A, Razzore P, Jaffrain-Rea M-L, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G 2000 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103
70. Caron P, Morange-Ramos I, Cogne M, Jaquet P 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22
71. Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G 1999 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40-47
72. Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, Attanasio R 2000 Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3:231-238
73. Lucas T, Astorga R, Catalá M, and the Spanish Multicentre Lanreotide Study Group on Acromegaly 2003 Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58:471-481
74. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe M, Albani G, Maiter D, Pagani MD, Legros J-J, Gianola D, Bex M, Poppe K, Mockel J, Pagani G 2000 Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577-584
75. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
76. Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J 1997 Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab 82:23-28
77. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC 1995 Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267-3272